Aurisco Pharmaceutical Co. Ltd. Class A

Aurisco Pharmaceutical Co. Ltd. Class A

SSSE:605116
16.80
CNY
-0.49
(-2.83%)
0.77EPS
25.64P/E
8.15BMarket Cap
Apr 22Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.64
1.46
1.6
1.62
1.93
2
2.48
3.1
3.7
4.23
4.14
Basic EPS, GAAP
0.24
0.12
0.38
0.52
0.42
0.42
0.52
0.71
0.89
1.12
0.78
Free Cash Flow per Basic Share
- -
0.03
0.04
0.3
0.15
-0.12
-0.12
0.2
-0.52
0.18
- -
Dividend per Share
0.21
0.16
0.1
- -
0.1
0.12
0.13
0.16
0.24
0.31
0.35
Book Value per Share
1.53
1.9
2.19
2.71
3.45
3.76
4.13
4.84
5.74
6.54
6.74
Tangible Book Value per Share
1.44
1.81
2.1
2.6
3.35
3.66
3.82
4.55
5.34
6.15
6.35
Basic Weighted Avg Shares
360
373
360
358
374
402
406
408
399
401
404
Sales/Revenue/Turnover
590
544
575
582
721
803
1,008
1,263
1,476
1,697
1,674
Operating Margin (%)
15.65
15.42
28.05
29.11
27.55
23.93
22.65
23.49
27.93
32.95
26.72
Depreciation Expense
- -
20
23
28
32
55
69
79
88
126
- -
Net Income, GAAP
87
45
137
186
157
169
211
289
355
449
317
Effective Tax Rate (%)
27.76
36.48
16.66
9.78
15.35
12.36
13.49
12.16
12.91
13.33
14.22
Profit Margin (%)
14.69
8.21
23.78
32
21.79
21
20.93
22.92
24.04
26.46
18.9
Working Capital
392
417
424
548
834
747
766
865
1,515
1,536
1,270
LT Debt
- -
- -
- -
- -
7
14
16
72
922
933
947
Total Equity
590
684
788
977
1,385
1,508
1,684
1,968
2,332
2,658
2,737
Return on Invested Capital (%)
- -
6.34
18.04
17.24
13.25
11.57
12.77
15.17
13.29
13.01
8.9
Return on Capital (%)
- -
6.84
18.34
21.09
13.26
11.62
13.15
15.29
13.74
13.87
9.73
Return on Common Equity (%)
- -
7.24
18.6
21.09
13.31
11.67
13.26
15.89
16.51
18.01
12.25

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
44
25
26
LT Borrowings
926
925
930
LT Finance Leases
24
20
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
406
406
406
Market Capitalization
11,938
7,685
8,152

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,026
1,858
1,747
Cash, Cash Equivalents & STI
917
721
601
Accounts Receivable, Net
418
426
374
Inventories
662
682
733
Total Current Liabilities
480
447
476
Payables & Accruals
- -
- -
- -
ST Debt
44
25
26
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.97%
13.98%
Free Cash Flow
- -
-188.23%
-134.36%
Net Income, GAAP
- -
23.75%
26.61%
Sales/Revenue/Turnover
- -
18.8%
15.03%
Total Cash Common Dividend
- -
28.57%
30.91%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
336
395
358
387
1,476
2025
402
420
- -
460
1,697
2026
389
439
386
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.26
0.24
0.18
0.89
2025
0.3
0.29
- -
0.23
1.12
2026
0.16
0.24
0.15
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.23
-0.01
0.02
0.24
2025
- -
0.29
- -
0.01
0.31
2026
- -
0.34
- -
- -
- -

Company Description

CEO
Ding Jun Chu
Full Time Employees
2,026
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Badu Industrial Park Zone Tiantai ZJ China 317200
IPO Date
Sep 21, 2020
Business
Aurisco Pharmaceutical Co.,Ltd. is an innovative international pharmaceutical enterprise dedicated to the research, development, production, and global commercialization of specialized active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company's diverse portfolio encompasses complex APIs for various therapeutic areas, including respiratory, cardiovascular, oncology, central nervous system, hormones, and anti-viral treatments. Aurisco also excels in advanced modalities such as peptides and oligonucleotides, developing sustainable processes backed by robust intellectual property. Additionally, the company provides comprehensive Contract Development and Manufacturing Organization (CDMO) services, guiding clients from initial research through development, regulatory approval, and commercial manufacturing. Established in 1998, Aurisco operates with its headquarters in Shanghai, China, and maintains a significant global footprint with multiple cGMP production facilities and R&D centers, actively serving the worldwide pharmaceutical market.

Company News

  • Aurisco Pharmaceutical est le premier fabricant mondial d'oligonucléotides génériques à avoir passé avec succès l'inspection de l'USFDA

  • Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA

  • Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA